Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 5/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521095 | 0.83 | CYP1A2 (0.48) | CYP2A6CYP1A2KIF11SMN1; SMN2MAPT | |
| SCHEMBL3267425 | 0.81 | CYP1A2 (0.46) | CYP2A6CYP1A2SMN1; SMN2MAPTHTT | |
| SCHEMBL3240202 | 0.78 | CYP1A2 (0.55) | CYP2A6CYP1A2KIF11SMN1; SMN2MAPT | |
| SCHEMBL13396491 | 0.78 | CDK1 (0.41) | CYP2A6CYP1A2MEN1KMT2AERN1 | |
| SCHEMBL10488244 | 0.77 | CYP1A2 (0.50) | CYP2A6CYP1A2KIF11SMN1; SMN2MAPT | |
| SCHEMBL5538295 | 0.77 | CYP1A2 (0.53) | CYP2A6CYP1A2KIF11SMN1; SMN2MAPT | |
| SCHEMBL29955696 | 0.77 | CYP1A2 (0.57) | CYP2A6CYP1A2MEN1KMT2AERN1 | |
| SCHEMBL9437612 | 0.77 | CYP1A2 (0.57) | CYP2A6CYP1A2MEN1KMT2AERN1 | |
| SCHEMBL4872417 | 0.76 | ALDH1A1 (0.46) | CYP1A2SMN1; SMN2MEN1KMT2AERN1 | |
| SCHEMBL7752839 | 0.74 | CYP1A2 (0.59) | CYP2A6CYP1A2KIF11SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | claimed |
| EP-2816409-A1 | Method for forming a resist under layer film and patterning process | Shin-Etsu Chemical Co., Ltd. (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-7396930-B2 | making spiro(benzo(c)thiophene-1 (3H),4'-piperidine) derivatives; involves reacting a mercapto compound with a 2-halophenylalkyl halide, reacting with an alkyllithium, then N-ethoxycarbonyl-4-piperidone, dehydration and cyclization; industrial scale; novel intermediates to neurokinin receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| CN-100334092-C | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO CO (JP) | 2007-08-29 | — | — | CN | disclosed |
| CN-1293052-C | Benzamidine derivatives | SANKYO CO (JP) | 2007-01-03 | — | — | CN | disclosed |
| EP-1245564-B1 | BENZAMIDINE DERIVATIVES | SANKYO CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| CN-1729196-A | Process for producing optically active sulfoxide | SANKYO CO (JP) | 2006-02-01 | — | — | CN | disclosed |
| CN-1675221-A | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO CO (JP) | 2005-09-28 | — | — | CN | disclosed |
| US-20050209262-A1 | Process for producing optically active sulfoxide | SANKYO COMPANY, LIMITED (JP) | 2005-09-22 | — | — | US | disclosed |
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO COMPANY, LIMITED (JP) | 2005-07-28 | — | — | US | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| CN-1413189-A | Benzamidine derivatives | SANKYO CO (JP) | 2003-04-23 | — | — | CN | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| CN-1216986-A | Isoxazole derivatives | SANKYO CO (JP) | 1999-05-19 | — | — | CN | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| CN-1162957-A | Isoxazole derivatives | SANKYO CO (JP) | 1997-10-22 | — | — | CN | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SULT1E1, TST, TMT1A | CYP2A6 197/4885CYP1A2 40/4885KIF11 4164/4885 |
| US-20050209262-A1 | Process for producing optically active sulfoxide | TST, TMT1A, PPOX | CYP2A6 381/4885CYP1A2 528/4885KIF11 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.